This study investigated the efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) based on neoadjuvant chemoradiotherapy (NCRT) on locally advanced rectal cancer (LARC) patients with clinically suspected positive LPLNs.


 All patients with clinically suspected positive LPLN received 56-60 Gy SIB-IMRT in the LPLN area.  The safety and efficacy of SIB-IMRT on clinically suspected positive LPLN of LARC patients were deemed acceptable. 
SIB-IMRT
This study investigated the efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) based on neoadjuvant chemoradiotherapy (NCRT) on locally advanced rectal cancer (LARC) patients with clinically suspected positive LPLNs.


 We retrospectively screened distal LARC patients with NCRT in our center from May 2016 and June 2019.  Patients did not exhibit in-field LPLN recurrence after NCRT combined with single total mesorectal excision (TME).
NCRT